Latigo Biotherapeutics, Inc. (LTGO): Results of Operations and Financial Condition
Latigo Biotherapeutics, Inc. (LTGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed upsized initial public offering, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $397.4 million;
How this was made
The 30-second read
Why it matters
The NEJM publication of onzotrigine results provides a credible, peer‑reviewed validation of the drug’s efficacy, likely prompting analyst upgrades and increased investor interest.
Market read
The filing combines financial results, a capital raise, and pivotal trial data, making it a high‑impact news item for biotech investors.
What to watch
The company’s cash runway to 2029 reduces near‑term financing risk, but dilution from the upsized IPO may pressure existing shareholders.
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
The company completed an upsized IPO raising gross proceeds of $397.4 million and projects that current cash and cash equivalents, including IPO net proceeds, will fund operating plans into 2029. Pipeline progress included NEJM publication of positive onzotrigine results and initiation of the LTG-321 Phase 2 trial, while the company remained pre-revenue and reported a GAAP net loss of $25.8 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash and cash equivalentsGAAP | $55.0 million | – | – |
| Cash and cash equivalents and restricted cashGAAP | $ 55,197 | – | – |
| Prepaid expenses and other current assetsGAAP | 4,002 | – | – |
| Operating lease right-of-use assetsGAAP | 1,303 | – | – |
| Property and equipment, netGAAP | 457 | – | – |
| Other assetsGAAP | 3,801 | – | – |
| Total assetsGAAP | $ 64,760 | – | – |
| Accounts payable, accrued expenses and other current liabilitiesGAAP | $ 15,825 | – | – |
| Operating lease liabilitiesGAAP | 1,353 | – | – |
| Derivative liabilityGAAP | 5,148 | – | – |
| Convertible promissory notesGAAP | 29,897 | – | – |
| Other long-term liabilitiesGAAP | 35 | – | – |
| Total liabilitiesGAAP | 52,258 | – | – |
| Redeemable convertible preferred stockGAAP | 288,582 | – | – |
| Total stockholders' deficitGAAP | (276,080 ) | – | – |
| Research and development expensesGAAP | $ 21,226 | – | – |
| General and administrative expensesGAAP | 4,582 | – | – |
| Total operating expensesGAAP | 25,808 | – | – |
| Loss from operationsGAAP | (25,808 ) | – | – |
| Interest incomeGAAP | (264 ) | – | – |
| Interest expenseGAAP | 251 | – | – |
| Change in fair value of preferred stock tranche liabilityGAAP | — | – | – |
| Other expense, netGAAP | 2 | – | – |
| Total other (income) expense, netGAAP | (11 ) | – | – |
| Net loss and comprehensive lossGAAP | $ (25,797 ) | – | – |
| Net loss and comprehensive loss per share — basic and dilutedGAAP | $ (27.59 ) | – | – |
| Weighted-average number of shares used in computing net loss per share — basic and dilutedGAAP | 935 | – | – |
| Stock-based compensation expensesGAAP | $2.1 million | – | – |
| Research and development expenses, six months ended June 30GAAP | $ 38,859 | – | – |
| General and administrative expenses, six months ended June 30GAAP | 10,385 | – | – |
| Total operating expenses, six months ended June 30GAAP | 49,244 | – | – |
| Loss from operations, six months ended June 30GAAP | (49,244 ) | – | – |
| Interest income, six months ended June 30GAAP | (738 ) | – | – |
| Interest expense, six months ended June 30GAAP | 251 | – | – |
| Change in fair value of preferred stock tranche liability, six months ended June 30GAAP | — | – | – |
| Other expense, net, six months ended June 30GAAP | 1 | – | – |
| Total other (income) expense, net, six months ended June 30GAAP | (486 ) | – | – |
| Net loss and comprehensive loss, six months ended June 30GAAP | $ (48,758 ) | – | – |
| Net loss and comprehensive loss per share — basic and diluted, six months ended June 30GAAP | $ (52.88 ) | – | – |
| Weighted-average number of shares used in computing net loss per share — basic and diluted, six months ended June 30GAAP | 922 | – | – |
Second half of 2026 and second half of 2027 outlook
- NotePlan to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with moderate-to-severe acute pain after bunionectomy surgery as well as a single-arm, open-label Phase 3 safety trial in the second half of 2026.
- NoteExpect to report topline results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027.
- NoteExpect to report topline results from the Phase 2 clinical trial of LTG-321 in the second half of 2027.
- NoteThe Company’s current cash and cash equivalents, including the net proceeds from its IPO, are projected to be sufficient to fund its current operating plans into 2029.
What drove it
- The New England Journal of Medicine published positive clinical trial results for onzotrigine in moderate-to-severe pain following abdominoplasty.
- The onzotrigine abdominoplasty study met its primary endpoint of the Summed Pain Intensity Difference over 48 hours versus placebo with high statistical significance and demonstrated rapid, clinically meaningful pain relief, favorable tolerability, and opioid-sparing potential.
- Latigo initiated a randomized, double-blind, placebo-controlled, within-patient crossover Phase 2 clinical trial of LTG-321 in approximately 120 patients with osteoarthritis of the knee, with enrollment underway.
- Completed bioavailability studies for the onzotrigine intravenous formulation, with preliminary data indicating approximately 100% oral bioavailability.
- Completed 14-day non-GLP toxicology studies for LTG-418, with suitable tolerability demonstrated in both rats and non-human primates.
Concerns
- Latigo reported a GAAP net loss and comprehensive loss of $ (25,797 ) for the three months ended June 30, 2026.
- The company has limited operating history and no history of commercializing products.
- The company has incurred substantial losses since its inception and may never achieve or maintain profitability.
- The company will require substantial additional financing to achieve its goals.
- Clinical-trial results or other studies may not support further development, and earlier results may not be predictive of future trials or real-world results.
What to watch
- Initiation of the onzotrigine Phase 3 bunionectomy trial and open-label Phase 3 safety trial in the second half of 2026.
- Topline results from the onzotrigine Phase 3 bunionectomy and open-label safety trials in the second half of 2027.
- Topline results from the LTG-321 Phase 2 trial in the second half of 2027.
- Progress of LTG-418 and the company's discovery efforts involving additional ion channel modulators.
- Execution against the stated expectation that current cash and cash equivalents, including IPO net proceeds, will fund current operating plans into 2029.
Balance sheet and cash flow
- Cash and cash equivalents were $55.0 million as of June 30, 2026.
- Completed an upsized initial public offering in August 2026, including the full exercise by the underwriters of their option to purchase additional shares, raising gross proceeds of $397.4 million, before deducting underwriting discounts and commissions and other offering expenses.
- Convertible promissory notes were 29,897 as of June 30, 2026.
- The Company’s current cash and cash equivalents, including the net proceeds from its IPO, are projected to be sufficient to fund its current operating plans into 2029.
Analysis
Latigo remained a clinical-stage and pre-revenue company in the second quarter ended June 30, 2026. It reported a GAAP net loss and comprehensive loss of $ (25,797 ), compared with $ (25,835 ) in the prior-year period. Research and development expense was $ 21,226 versus $ 22,924, while general and administrative expense was 4,582 versus 2,821. Total operating expenses were 25,808, compared with 25,745, leaving loss from operations at (25,808 ).
The balance sheet at June 30 showed cash and cash equivalents and restricted cash of $ 55,197, total assets of $ 64,760, total liabilities of 52,258, and total stockholders' deficit of (276,080 ). Subsequent to quarter-end, the company completed an upsized IPO in August 2026 that raised gross proceeds of $397.4 million before underwriting discounts, commissions and other offering expenses. Management stated that current cash and cash equivalents, including IPO net proceeds, are projected to fund current operating plans into 2029.
The principal operating development was publication in The New England Journal of Medicine of positive onzotrigine abdominoplasty results. The company said the study met its primary endpoint versus placebo with high statistical significance and showed rapid, clinically meaningful pain relief, favorable tolerability and opioid-sparing potential. The company also completed bioavailability studies for the intravenous formulation, with preliminary data indicating approximately 100% oral bioavailability.
Pipeline execution advanced beyond onzotrigine. Latigo initiated its LTG-321 Phase 2 trial in approximately 120 osteoarthritis-of-the-knee patients, with enrollment underway at multiple sites in Denmark. It also completed 14-day non-GLP toxicology studies for LTG-418, reporting suitable tolerability in rats and non-human primates. The company plans to initiate onzotrigine Phase 3 bunionectomy and open-label safety trials in the second half of 2026.
The disclosed forward timeline concentrates key clinical readouts in the second half of 2027, when the company expects topline results from both the onzotrigine Phase 3 trials and the LTG-321 Phase 2 trial. Financially, the filing contains no revenue, gross margin, operating cash flow, free cash flow, non-GAAP earnings measure, repurchase or dividend disclosure. The period therefore centers on financing runway and clinical development milestones rather than commercial operating performance.
Management, verbatim
This has been a significant period for Latigo as we completed our upsized initial public offering, published positive onzotrigine abdominoplasty results in moderate-to-severe acute pain in The New England Journal of Medicine, and continued to advance our pipeline of innovative pain programs.
Nima Farzan, chief executive officer of Latigo
With a strong balance sheet, a highly experienced team, and a portfolio of differentiated programs, we are focused on executing our development plans, including the initiation of the Phase 3 program for onzotrigine and the advancement of onzotrigine and LTG-321 toward key future milestones.
Nima Farzan, chief executive officer of Latigo
Not in the filing
stated, not guessed- Revenue
- Revenue growth
- Segment revenue and segment comparisons
- Gross profit and gross margin
- Operating income as a positive income measure
- Income tax expense or benefit and tax rate
- Non-GAAP financial measures
- Operating cash flow
- Free cash flow
- Capital expenditures
- Share repurchases
- Dividends
- Explicit revenue, gross-margin, operating-expense or tax-rate guidance
- Prior outlook for comparison against reported results
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Latigo Biotherapeutics, a Nasdaq‑listed clinical‑stage biotech, disclosed its Q2 2026 financials and highlighted recent clinical progress.
Ticker impact
Latigo Biotherapeutics filed an 8‑K reporting Q2 2026 results and positive NEJM trial data for onzotrigine in acute pain.
Potential short‑term price rally of 10‑15% if market digests the data positively.
Clinical‑trial success is a material catalyst for a clinical‑stage biotech; the company also raised $397 M in its IPO, providing runway to 2029.
Market effects
Strengthens the non‑opioid pain‑management biotech sector and may lift peer valuations.
Positive for U.S. biotech listings and related Nasdaq biotech indices.
Highlights emerging non‑opioid therapies, relevant to global pain‑management markets.
Counterpoint
If the Phase 3 data fail to meet expectations, the stock could face a sharp correction despite the hype.
Key entities
- companyLatigo Biotherapeutics, Inc.
Clinical‑stage biotech developing non‑opioid pain medicines (ticker LTGO).
- executiveNaomi Lowy, M.D.
Appointed senior VP of global regulatory affairs.
